Clinical Trial Update: Lymphangioleiomyomatosis (LAM) Registry

View source ↗

Summary

An update on the Lymphangioleiomyomatosis (LAM) patient registry sponsored by NHLBI; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphangioleiomyomatosis

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Lung Diseases, Lymphangiomyomatosis | Status: COMPLETED